Previous 10 | Next 10 |
Despite most of the world putting their attention towards COVID-19, cardiovascular disease is still the world-leading healthcare crisis. Esperion Therapeutics ( ESPR ) is attempting to alleviate that enduring problem with its affordable, convenient, oral, once-daily, non-statin, LDL-C medicine...
We have established a position in Esperion Therapeutics ( ESPR ), buying 500 shares at $44.92 on May 14 for the SHU portfolio. The investment thesis is very simple; It has two FDA approved drugs that lower LDL cholesterol for people who can't use statins. The market for these is very l...
Esperion Therapeutics ( ESPR ) recently caught my eye because of a newly announced 256% upside target from Needham. This article reflects my evaluation of Esperion as an investment vehicle. Esperion Therapeutics is a small biotech with a tightly focused mission of lipid management Esperi...
Needham's look at lipid management company Esperion Therapeutics (NASDAQ: ESPR ) builds off a few weeks of sales data for its recently approved lead product, numbers it sees as quite strong in a pandemic environment that has forced remote access and training. More news on: Esperion Therape...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Esperion Therapeutics Inc (NASDAQ: ESPR) Q1 2020 Earnings Call May 6, 2020 , 4:30 p.m. ET Operator Continue reading
ANN ARBOR, Mich., May 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that president and chief executive officer, Tim M. Mayleben, will participate in an analyst-led fireside chat at the BofA Securities 2020 Healthcare Conference on Tuesday, May 12, 2020, at 9:00 a.m. ...
Esperion Therapeutics, Inc. (ESPR) Q1 2020 Earnings Conference Call May 6, 2020 4:30 PM ET Company Participants Alex Schwartz – Head-Investor Relations Tim Mayleben – President and Chief Executive Officer Mark Glickman – Chief Commercial Officer Rick Bartra...
Esperion Therapeutics (NASDAQ: ESPR ): Q1 GAAP EPS of -$2.84 beats by $0.49 . Revenue of $1.8M (-98.8% Y/Y) beats by $1.41M . Press Release More news on: Esperion Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,
Company Secures Marketing Approvals for NEXLETOL™ and NEXLIZET™ Tablets in the U.S. as well as for NILEMDO™ and NUSTENDI™ Tablets in Europe NEXLETOL™ (bempedoic acid) Tablets Commercially Available in the U.S. on March 30 th NEXLIZET™...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...